Key Highlights
- COCP shares are trading down 1.03% at $0.97, versus a prior close of $0.98.
- Loss of $0.20 per share was wider than the $0.14 market estimate.
- Third-quarter net loss was $3.444 million, versus $2.049 million a year earlier.
- The last subject was dosed in the Phase 1b norovirus challenge study in September.
Cocrystal Pharma (NASDAQ:COCP) shares are trading slightly lower today after the company filed third-quarter results with a $3.444 million net loss, compared with $2.049 million a year earlier. The loss of $0.20 per share was wider than the $0.14 market estimate, and the filing says the nine-month loss and cash use raise substantial doubt about continuing as a going concern.
The clinical-stage company develops antiviral drugs for RNA viruses including norovirus, influenza and coronaviruses using structure-based technology.
Norovirus Program Moves Past Dosing
Its lead candidate, oral CDI-988, is a protease inhibitor being tested in a Phase 1b human challenge study at Emory University School of Medicine, which began in February. The company said the last subject was dosed in September, and the FDA granted the drug Fast Track Designation in April.
Earlier Phase 1 work in healthy volunteers showed favorable safety and tolerability across doses up to 1200 mg.
Nine-Month Loss and Influenza Dispute Weigh on the Outlook
For the nine months, the net loss rose to $8.907 million from $6.405 million, and operations used $7.153 million in cash. The auditor's report includes an explanatory paragraph on going concern.
A Phase 2a influenza study of CC-42344 in the United Kingdom produced favorable safety results but failed to give a usable efficacy readout because of low infection among participants. The company has asked the research organization to refund the $6,309,000 it was paid or repeat the study, and the organization disputes the claim. A $500,000 federal small Business research award was announced in October 2025.
Outlook: Challenge Study Results and Funding Are the Next Tests
The report highlights progress in the norovirus program alongside a limited funding position. Investors will watch for Phase 1b data, any resolution of the influenza dispute and financing plans.






Please wait processing your request...